<DOC>
	<DOCNO>NCT00745550</DOCNO>
	<brief_summary>The study consist two phase : The first portion study Phase 1 dose escalation study determine maximum tolerate dose dose limit toxicity SB1518 give single agent orally daily subject Chronic Idiopathic Myelofibrosis ( CIMF ) regardless JAK2 mutational status . The second portion study Phase 2 study define efficacy safety profile single agent SB1518 recommend dose subject CIMF .</brief_summary>
	<brief_title>A Phase 1/2 Study Oral SB1518 Subjects With Chronic Idiopathic Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>Inclusion Criteria Subjects CIMF ( include post ET/PV MF ) require therapy , include : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Men reproductive potential agree practice effective contraception entire study period one month last study treatment Women childbearing potential negative pregnancy test within 14 day prior first dose study drug agree practice effective contraception entire study period one month last study treatment , unless documentation infertility exist Subjects able understand willing sign inform consent form Exclusion Criteria Subjects uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement judge treat physician . Subjects receive antibiotic infection control may include study unless antibiotic CYP3A4 inducer/inhibitor Subjects know HIVpositive Subjects know active hepatitis A , B , C , latent hepatitis B Women pregnant lactating Subjects prior radiation therapy 20 % hematopoietic marrow ( prior radiation spleen allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>SB1518</keyword>
	<keyword>Chronic Idiopathic Myelofibrosis</keyword>
	<keyword>Myeloproliferative disorder</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>JAK2 inhibitor</keyword>
</DOC>